RAC Investor Hub Q&A, page-7

I didn’t post in the hub but sent an email to DCB requesting a Q&A session with SHs following the not so clear quarterly and got the below response:

Thanks for your email. Appreciate your thoughts Glad you took the time to read the quarterly report. The report is designed to re-cap though always to inform with appropriate governance.

Just to highlight the direction as advised within the quarterly, we are taking to the next 3months:"We now move toward a planned strategic collaborative meeting with key opinion leaders in the last days of April, as we look to continue the team’s significant momentum. We are encouraged by the development of our new formulation, RC220 and our scientific results. With collaboration from our experienced scientific agency, Adnovate and our new team of clinical advisors, we are actively moving to further define our Target Product Profiles for Zantrene and to facilitate a clinical advisory board by June, enabling prioritisation of our resources and leading to enhancement of our Clinical Development Plans (CDP) by July/August. We will then be well positioned to execute on strategic commercialisation priorities for 2023 and beyond".

As suggested that by July/August the above work will be completed, and this will include clear and directional communication. I expect more communication in way of several press releases in the meantime. I am positive this will provide the ongoing expectation of transparent communication.

As suggested, we are confident in the program and the team, We are actively moving the strategy forward and optimising it as we should. As you can see form the report, there is plenty of work in progress. Updates to expect were towards the end of the report. We look forward to a positive 2023.

—— — —

So there is no plan to have a Q&A session with SHs as requested but Damian has reiterated the July/ August timeframe which in my mind means a likely new direction (new set of pillars?) most likely leading to some form of M&A. Looks positive and confident.